San Diego, CA  (June 27, 2017) – January Therapeutics, Inc., a biotechnology company discovering and developing novel nanoparticle therapeutics, today announced completion of its Series A financing.  This funding will be used to advance its initial target program, which has applications in pancreatic, lung and ovarian cancers, as well as to build the company’s technology platform and pipeline.  Both institutional and private investors participated in this round.

“We thank the investors for the trust they have placed in us and share in their excitement for this opportunity,” said Robin Jackman, Chief Executive Officer of January Therapeutics.  “We look forward to continuing in the rapid advancement of our lead oncology program and expansion of our underlying technology.”

About January Therapeutics, Inc.

January Therapeutics is a biotechnology company focusing on discovery of novel cancer therapeutics that leverage the proven clinical benefits of albumin nanoparticle formulations.  Building upon the finding that albumin nano-formulations drive substantial improvements in the efficacy of known drugs, the company’s goal is to create novel drugs with superior efficacy and reduced toxicity in hard-to-treat malignancies. Initial applications are in advanced pancreatic, lung, and ovarian cancers.  January Therapeutics was founded in 2016 and is located in San Diego, CA